NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Andries, Vanessa ^a,b   Vandepoele, Karl ^a,b,c   Staes, Katrien ^a   Berx, Geert ^a,b   Bogaert, Pieter ^a,d   Isterdael, Gert ^a,b   Ginneberge, Daisy ^a   Parthoens, Eef ^a,b   Vandenbussche, Jonathan ^a,b   Gevaert, Kris ^a,b   Roy, Frans ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d BARC Global Central Laboratory   (Belgium)

Author keywords

Cancer; Cell cycle; G1 arrest; NBPF; p21; p53; Tumor suppressor

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NEUROBLASTOMA BREAKPOINT FAMILY MEMBER 1 PROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; NBPF1 PROTEIN, HUMAN; PROTEOME;

ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; SQUAMOUS EPITHELIUM; TANDEM MASS SPECTROMETRY; UPREGULATION; UTERINE CERVIX; WESTERN BLOTTING; EPITHELIUM; GENETIC TRANSFECTION; GENETICS; METABOLISM; MULTIGENE FAMILY; PATHOLOGY; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARRIER PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EPITHELIUM; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENES, REPORTER; HEK293 CELLS; HUMANS; MULTIGENE FAMILY; NEUROBLASTOMA; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84929391388     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1408-5     Document Type: Article

References (29)

1. Laureys G, Speleman F, Opdenakker G, Benoit Y, Leroy J. Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma. Genes Chromosomes Cancer. 1990;2:252-4.
2. Laureys G, Speleman F, Versteeg R, van der Drift P, Chan A, Leroy J, et al. Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers. Oncogene. 1995;10:1087-93.
3. Vandepoele K, Andries V, Van Roy N, Staes K, Vandesompele J, Laureys G, et al. A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes (p. 1-12). PLoS One. 2008;3, e2207.
4. Vandepoele K, Van Roy N, Staes K, Speleman F, van Roy F. A novel gene family NBPF: Intricate structure generated by gene duplications during primate evolution. Mol Biol Evol. 2005;22:2265-74.
5. Popesco MC, Maclaren EJ, Hopkins J, Dumas L, Cox M, Meltesen L, et al. Human lineage-specific amplification, selection, and neuronal expression of DUF1220 domains. Science. 2006;313:1304-7.
6. O'Bleness MS, Dickens CM, Dumas LJ, Kehrer-Sawatzki H, Wyckoff GJ, Sikela JM. Evolutionary history and genome organization of DUF1220 protein domains. G3 (Bethesda). 2012;2:977-86.
7. Andries V, Vandepoele K, van Roy F. The NBPF Gene Family. In: Shimada H, editor. Neuroblastoma-Present and Future. Rijeka, Croatia: InTech; 2012. p. 185-214.
8. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17:2264-79.
9. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol. 2009;5:625-39.
10. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009;459:987-91.
11. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68:2551-6.
12. Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine JC, et al. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther. 2011;10:983-93.
13. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:0034.1-11.
14. Kaur P. Interfollicular epidermal stem cells: identification, challenges, potential. J Invest Dermatol. 2006;126:1450-8.
15. Fuchs E. Scratching the surface of skin development. Nature. 2007;445:834-42.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
17. Ghesquiere B, Jonckheere V, Colaert N, Van Durme J, Timmerman E, Goethals M, et al. Redox proteomics of protein-bound methionine oxidation. Mol Cell Proteomics. 2011;10:M110 006866.
18. Colaert N, Helsens K, Impens F, Vandekerckhove J, Gevaert K. Rover: a tool to visualize and validate quantitative proteomics data from different sources. Proteomics. 2010;10:1226-9.
19. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-25.
20. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55:5187-90.
21. Attardi LD, DePinho RA. Conquering the complexity of p53. Nat Genet. 2004;36:7-8.
22. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, et al. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 1997;15:2767-72.
23. Anderson CW, Appella E, Sakaguchi K. Posttranslational modifications involved in the DNA damage response. J Protein Chem. 1998;17:527.
24. Joseph P, O'Kernick CM, Othumpangat S, Lei YX, Yuan BZ, Ong TM. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog. 2004;40:171-9.
25. Ha SA, Shin SM, Namkoong H, Lee H, Cho GW, Hur SY, et al. Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis. Clin Cancer Res. 2004;10:8386-95.
26. Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005;24:425-39.
27. Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res. 2004;10:651-7.
28. Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids. 2011;41:893-9.
29. Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, et al. Functional evidence implicating S100P in prostate cancer progression. Int J Cancer. 2008;123:330-9.